New Biochemical Approaches for Treatment of Glioblastoma.

IF 4 2区生物学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Journal of Biological Chemistry Pub Date : 2025-09-20 DOI:10.1016/j.jbc.2025.110748

Laura A Lindsey-Boltz,Aziz Sancar

引用次数: 0

Abstract

Glioblastoma is a relatively common form of brain tumor for which at present there is no efficient surgical or pharmaceutical treatment. Even with the standard-of-care consisting of surgery, radiotherapy, plus temozolomide (TMZ) treatment, the median survival time is around 12 months. Recently, several new chemotherapeutic approaches have been developed that target DNA or the circadian clock for treating glioblastoma. Here after briefly reviewing the standard of care, TMZ, we summarize the mechanistic bases of these new approaches and their potential for improving treatment of glioblastoma and other brain tumors.

查看原文本刊更多论文

治疗胶质母细胞瘤的新生化方法。

胶质母细胞瘤是一种相对常见的脑肿瘤，目前尚无有效的手术或药物治疗方法。即使采用由手术、放疗和替莫唑胺（TMZ）治疗组成的标准治疗，中位生存时间也在12个月左右。最近，一些新的化疗方法已经开发出靶向DNA或生物钟来治疗胶质母细胞瘤。在简要回顾了治疗标准TMZ后，我们总结了这些新方法的机制基础及其在改善胶质母细胞瘤和其他脑肿瘤治疗方面的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Biological Chemistry Biochemistry, Genetics and Molecular Biology-Biochemistry

自引率

4.20%

发文量

1233

期刊介绍： The Journal of Biological Chemistry welcomes high-quality science that seeks to elucidate the molecular and cellular basis of biological processes. Papers published in JBC can therefore fall under the umbrellas of not only biological chemistry, chemical biology, or biochemistry, but also allied disciplines such as biophysics, systems biology, RNA biology, immunology, microbiology, neurobiology, epigenetics, computational biology, ’omics, and many more. The outcome of our focus on papers that contribute novel and important mechanistic insights, rather than on a particular topic area, is that JBC is truly a melting pot for scientists across disciplines. In addition, JBC welcomes papers that describe methods that will help scientists push their biochemical inquiries forward and resources that will be of use to the research community.